Atalanta Therapeutics
Atalanta Therapeutics is pioneering new treatment options for neurodegenerative diseases using its proprietary RNA interference platform. Founded in 2018 by leading experts in RNAi, the company develops innovative therapies targeting CNS diseases, with a focus on delivering effective treatments through its unique di-siRNA technology. With strategic collaborations and a robust pipeline, Atalanta aims to address unmet medical needs in neurodegeneration and CNS disorders.
Industries
Nr. of Employees
small (1-50)
Atalanta Therapeutics
51 Sleeper Street, 7th Floor, Boston, MA 02210
Products
Investigational RNAi therapy targeting KCNT1 for genetic epilepsy
Preclinical investigational oligonucleotide designed to reduce KCNT1 expression and normalize neuronal excitability; single-dose CSF administration produced durable seizure suppression in mouse models with planned IND submission.
Investigational RNAi therapy targeting HTT for Huntington’s disease
Preclinical oligonucleotide program designed to silence huntingtin (HTT) transcript throughout the CNS with demonstrated deep-brain knockdown and multi-month duration in preclinical models.
Investigational RNAi therapies targeting Alzheimer's disease-associated genes
Preclinical programs aimed at modulating Alzheimer’s-related targets such as APOE and CD33 using sequence-directed oligonucleotide therapeutics designed for CNS distribution.
Investigational RNAi therapy targeting SCN9A for pain indications
Preclinical program to reduce expression of a pain-related sodium channel gene for indications such as trigeminal neuralgia, developed using CNS-capable oligonucleotide scaffolds.
Oligonucleotide therapeutic platform for CNS distribution
A programmable oligonucleotide scaffold designed to support delivery, predictable safety profile and rapid generation of candidate sequences against diverse CNS targets.
Investigational RNAi therapy targeting KCNT1 for genetic epilepsy
Preclinical investigational oligonucleotide designed to reduce KCNT1 expression and normalize neuronal excitability; single-dose CSF administration produced durable seizure suppression in mouse models with planned IND submission.
Investigational RNAi therapy targeting HTT for Huntington’s disease
Preclinical oligonucleotide program designed to silence huntingtin (HTT) transcript throughout the CNS with demonstrated deep-brain knockdown and multi-month duration in preclinical models.
Investigational RNAi therapies targeting Alzheimer's disease-associated genes
Preclinical programs aimed at modulating Alzheimer’s-related targets such as APOE and CD33 using sequence-directed oligonucleotide therapeutics designed for CNS distribution.
Investigational RNAi therapy targeting SCN9A for pain indications
Preclinical program to reduce expression of a pain-related sodium channel gene for indications such as trigeminal neuralgia, developed using CNS-capable oligonucleotide scaffolds.
Oligonucleotide therapeutic platform for CNS distribution
A programmable oligonucleotide scaffold designed to support delivery, predictable safety profile and rapid generation of candidate sequences against diverse CNS targets.
Services
Collaborative discovery and preclinical development partnerships with biopharmaceutical companies including joint target programs, data sharing and milestone-based development.
Collaborative discovery and preclinical development partnerships with biopharmaceutical companies including joint target programs, data sharing and milestone-based development.
Expertise Areas
- RNA interference therapeutics for CNS diseases
- Oligonucleotide chemistry and synthesis
- Preclinical in vivo pharmacology
- Bioanalytics and PK/PD
Key Technologies
- Branched/divalent siRNA constructs for CNS delivery
- Automated oligonucleotide synthesizers
- Preparative and analytical HPLC
- Liquid chromatography–mass spectrometry (LC‑MS)
News & Updates
Preclinical data demonstrating proof-of-mechanism of ATL-201 in a mouse model, showing seizure suppression for 6 months.
Funding to support Phase 1 trials for ATL-201 and ATL-101 for neurological diseases.
Company launched with Series A funding and collaborations with Biogen and Genentech.
A study demonstrating durable seizure suppression with ATL-201 in a preclinical model.
Research showing effective gene silencing in primate brain models.
Preclinical data on pain relief through gene silencing.
Preclinical data demonstrating proof-of-mechanism of ATL-201 in a mouse model, showing seizure suppression for 6 months.
Funding to support Phase 1 trials for ATL-201 and ATL-101 for neurological diseases.
Company launched with Series A funding and collaborations with Biogen and Genentech.
A study demonstrating durable seizure suppression with ATL-201 in a preclinical model.
Research showing effective gene silencing in primate brain models.
Preclinical data on pain relief through gene silencing.